p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification

子宫内膜癌 医学 浆液性液体 肿瘤科 内科学 癌症 癌症研究
作者
Amy Jamieson,Emily F. Thompson,Jutta Huvila,C. Blake Gilks,Jessica N. McAlpine
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:31 (6): 907-913 被引量:65
标识
DOI:10.1136/ijgc-2020-002256
摘要

Over the past decade, our understanding of endometrial cancer has changed dramatically from the two-tiered clinicopathologic classification system of type I and type II endometrial cancer through to the four distinct molecular subtypes identified by The Cancer Genome Atlas (TCGA) in 2013. In both systems there is a small subset of endometrial cancers (serous histotype/high numbers of somatic copy number abnormalities) that account for a disproportionately high percentage of endometrial cancer related deaths. This subset can be identified in routine clinical practice by first identifying the approximately one-third of endometrial cancers that are either ultramutated/ POLE mut tumors, with pathogenic mutations in the exonuclease domain of POLE , or hypermutated/MMRd tumors, with loss of DNA mismatch repair. Immunostaining for p53 stratifies the remaining endometrial cancers into those with wild-type staining pattern and those with mutant pattern staining (p53abn endometrial cancer). This latter group of p53abn endometrial cancer is the subject of this review. Most p53abn endometrial cancers are serous type and high grade, but it also includes other histotypes and lower grade tumors, and has consistently been associated with the poorest clinical outcomes. Although it only accounts for 15% of all endometrial cancer cases, it is responsible for 50–70% of endometrial cancer mortality. A better understanding of the molecular alterations in the p53abn subgroup, beyond the ubiquitous and definitional TP53 mutations, is required so we can identify better treatments for these most aggressive endometrial cancers. Recent evidence has shown improved survival outcomes with the addition of chemotherapy compared with radiation alone in p53abn endometrial cancers. Opportunities for targeted therapy for p53abn endometrial cancers also exist with a proportion of p53abn endometrial cancers known to have homologous recombination deficiency (HRD) or human epidermal growth factor 2 (HER2) overexpression/amplification. This review will provide an overview of our current understanding of p53abn endometrial cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanmiao12完成签到,获得积分10
1秒前
香蕉觅云应助momo采纳,获得10
3秒前
4秒前
5秒前
爆米花应助李春鸿采纳,获得10
8秒前
LJJ发布了新的文献求助10
9秒前
10秒前
11秒前
12秒前
12秒前
Ava应助YYH采纳,获得10
12秒前
量子星尘发布了新的文献求助10
12秒前
小田心完成签到,获得积分10
12秒前
15秒前
小田心发布了新的文献求助10
15秒前
WYH发布了新的文献求助10
16秒前
一方通行发布了新的文献求助10
16秒前
SherlockHe发布了新的文献求助10
17秒前
FashionBoy应助热情的达采纳,获得10
17秒前
20秒前
lelelele发布了新的文献求助10
21秒前
拜拜完成签到,获得积分10
22秒前
22秒前
扶苏完成签到,获得积分10
22秒前
24秒前
mmm完成签到,获得积分20
25秒前
momo发布了新的文献求助10
25秒前
25秒前
一方通行完成签到,获得积分10
25秒前
xiaosu完成签到,获得积分10
26秒前
小马甲应助yyy采纳,获得10
29秒前
热情的达发布了新的文献求助10
29秒前
Hello应助任性的咖啡采纳,获得10
30秒前
30秒前
墨墨完成签到,获得积分10
30秒前
31秒前
cangy完成签到,获得积分10
32秒前
岸部完成签到,获得积分10
32秒前
在水一方应助WYH采纳,获得10
33秒前
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173